Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Shares Outstanding (Diluted Average) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 325.83% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 325.83% year-over-year, with the annual reading at $1.7 million for FY2025, 325.83% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $1.7 million at bioAffinity Technologies, up from $1.1 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $24.0 million in Q2 2025, with the low at $374445.0 in Q3 2024.
  • Average Shares Outstanding (Diluted Average) over 4 years is $7.3 million, with a median of $8.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) tumbled 95.69% in 2024, then soared 325.83% in 2025.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $4.5 million in 2022, then skyrocketed by 94.43% to $8.7 million in 2023, then plummeted by 95.38% to $404167.0 in 2024, then skyrocketed by 325.83% to $1.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $1.7 million, $1.1 million, and $24.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.